A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer (Q33332587)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Gilberto Schwartsmann

object named as

G Schwartsmann

1

0 references

author name string

H Schunemann

2

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

C N Gorini

3

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

A F Filho

4

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

C Garbino

5

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

G Sabini

6

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

I Muse

7

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

L DiLeone

8

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

D R Mans

9

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

publication date

1 February 2000

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

83-91

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro cytotoxic and biochemical effects of 5-aza-2'-deoxycytidine

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Growth inhibitory effects of 5-aza-2'-deoxycytidine in HL-60 promyelocytic leukemia cells resistant to differentiation induction.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resistance of HL-60 promyelocytic leukemia cells to induction of differentiation and its reversal by combination treatment.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy in non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reporting results of cancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EORTC New Drug Development Office coordinating and monitoring programme for phase I and II trials with new anticancer agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations

1 reference

https://pubmed.ncbi.nlm.nih.gov/10830142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1023/A:1006388031954

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33332587&oldid=2195252119"